Dupilumab in combination with other biologic agents is safe and effective for treating various chronic inflammatory conditions.

Astegolimab, an anti-ST2 monoclonal antibody designed to block signaling of IL-33 under development by Roche's (OTCQX:RHHBY) Genentech unit, failed to meet its primary endpoint in a phase 3 trial for ...

Regeneron Pharmaceuticals sees strength in Dupixent, oncology gains, and major buybacks despite setbacks. Find out why REGN ...

NEW YORK CITY, NY / ACCESS Newswire / July 9, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sanofi ( ...

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms.

Itepekimab as add-on maintenance treatment for moderate to severe chronic obstructive pulmonary disease [ID6547] ...

In AERIFY-2, however, itepekimab failed to hit this same threshold, showing only a 2% reduction in exacerbations at 52 weeks. “Sentiment has undoubtedly been poor for REGN shares of late following the ...

RBC Capital also reaffirmed its Sector Perform rating with a $662 price target, following challenges with the itepekimab program. RBC’s investor survey indicated a desire for strategic changes, such ...

On May 30, 2025, Sanofi issued a press release announced mixed data from a Phase 3 program for itepekimab, an antibody therapy targeting the lung disorder chronic obstructive pulmonary disease ...